Mangata Networks Selected by 5G Open Innovation Lab to Help Drive Early Adoption and Innovation of 5G Technology
16.9.2020 19:00:00 EEST | Business Wire | Press release
Mangata Networks announced today that it has been selected as a member of the 5G Open Innovation Lab, a global ecosystem of developers, start-ups, enterprises, academia and government institutions, focused on helping start-ups utilize 5G to develop new capabilities, use cases and market categories. Mangata Networks will work closely with the Lab’s founding partners including Intel, T-Mobile and other partners to further develop its 5G over satellite network solution. MangataEdgeTM will be a bit more than a satellite terminal integrating microEdge cloud computing with 5G radio access networking capability.
Brian Holz, CEO of Mangata Networks said “the 5G Open Innovation Lab is a fantastic opportunity for our team. We look forward to working with TMobile, Intel and their partners to further develop and define our core terrestrial networking product, ensuring seamless integration into 5G networks at affordable costs. MangataEdgeTM will allow operators to bring the cloud directly to businesses, communities and individuals, enabling them to effectively do their bit.”
Unique to the Lab’s approach is its focus on unifying an independent ecosystem by bringing together technology, financial and community partners and forward-thinking customers from industries such as media and entertainment, transportation, oil and gas, manufacturing, and retail.
Integrating satellite over 5G in a seamless, cost-effective manner enables information exchange and service delivery by communities and individuals not well connected today. The 5G Open Innovation Lab will give Mangata Networks access to leading edge technology, partnerships, resources, and environment to ensure their 5G product is a success.
“The 5G OI Lab is an extraordinary opportunity for developers to work directly with technology and business leaders to design and bring to life their vision and dreams for new 5G applications,” said Jim Brisimitzis, managing partner of the 5G OI Lab. “This is not just any startup program. We are building a true partner ecosystem that will bring knowledge, resources and capital together to change the world in profound ways.”
About the 5G Open Innovation Lab
The 5G Open Innovation Lab (5G OI Lab) is a global ecosystem of developers, start-ups, enterprises, academia and government institutions working together to fuel the development of new 5G capabilities and market categories that will transform the way we work, live and play both now and in the future. The Lab provides developers at all stages unparalleled access to open platforms, enterprises and markets needed to create, test and deploy new use cases and innovations for 5G. To learn more about the Lab and its portfolio of companies, please visit https://www.5GOILab.com/ or follow us on Twitter at @5GOILab.
About Mangata Networks
Mangata Networks, a joint venture with Intellectual Ventures Invention Science Fund, is a satellite enabled telecommunications company seeking to transform human potential into action. Our solution: creating a seamless global network to support businesses, communities, and individuals to do their bit. Our single core network allows rapid scaling of data connectivity across geographies. With a global footprint, our technology can be mobilized by businesses to reach their highest potential anywhere at an affordable price. To learn more about Mangata Networks, please visit https://www.mangatanetworks.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005591/en/
Contact information
Calysto Communications
Laura Borgstede
Lborgstede@calysto.com
404-266-2060 x. 11
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom